Acromegaly

This study follows 200 people with acromegaly who are using octreotide subcutaneous depot, a medication that helps control hormone levels. Researchers will monitor safety and effectiveness for up to two years in everyday clinical practice, not a controlled lab setting. The goal i…

This phase 3 trial tests a new long-acting version of the drug octreotide (Debio 4126) for people with acromegaly, a condition caused by too much growth hormone. The drug is given as a shot every 12 weeks, instead of the usual monthly injections. The study will compare it to a pl…

This Phase 1 trial tests the safety of a new drug called MAR002 in 45 healthy men. Participants receive either MAR002 or a placebo by injection. The goal is to see if it's safe and how the body processes it, before testing it in people with acromegaly.

This study looks at whether the drug Pasireotide LAR can reduce the risk of spine fractures in people with acromegaly better than another drug, Pegvisomant. Acromegaly is a condition where too much growth hormone weakens bones, leading to painful fractures. Researchers will follo…

This early study tests a special PET/MRI scan using a radioactive tracer called FET to find small pituitary tumors that don't show up on regular MRI. The goal is to improve detection of these hormone-producing tumors in 5 adults with confirmed biochemical disease. If the scan wor…

This study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…

This study aims to find new genes that cause pituitary tumors, including those that lead to acromegaly (gigantism) and prolactinomas. Researchers will collect blood and tissue samples from up to 10,000 people with these tumors and their family members. By analyzing DNA, they hope…